<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382732</url>
  </required_header>
  <id_info>
    <org_study_id>MHST2011-06</org_study_id>
    <nct_id>NCT01382732</nct_id>
  </id_info>
  <brief_title>Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia</brief_title>
  <official_title>Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Thomas Hospital, Panama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Thomas Hospital, Panama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum hemorrhage is an important cause of maternal morbidity and mortality. In patients
      with severe preeclampsia there is an increased risk of postpartum hemorrhage but the
      hemodynamic changes associated with this pathology make the management of any kind of
      bleeding particularly troublesome. There are many pharmacological options, being oxytocin the
      first line of treatment. However there is no evidence about the safety and efficacy of
      carbetocin, an oxytocin agonist. The investigators aimed to compare oxytocin with carbetocin
      for the routine prevention of postpartum hemorrhage in patients with severe preeclampsia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for additional uterotonics</measure>
    <time_frame>Six months</time_frame>
    <description>Number of cases allocated to one arm of the study that due to the presence of continous bleeding postpartum need the use of an additional uterotonic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of oliguria</measure>
    <time_frame>six months</time_frame>
    <description>Number of cases that develop oliguria (&lt;30 mL/hr over a 2 hour period) after the administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hemodynamic status</measure>
    <time_frame>six months</time_frame>
    <description>Changes in Systolic pressure , dyastolic pressure, mean arterial pressure and heart rate one and two hours after the administration of the drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">636</enrollment>
  <condition>Severe Preeclampsia</condition>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
Ringer's Lactate 4mL applied to a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protocol B (oxytocin + placebo) Ringer's Lactate 11mL directly into the vein in no less than two minutes. Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.</description>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Lonactene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women between 28 weeks and term

          -  Severe pre-eclampsia

        Exclusion Criteria:

          -  Twin pregnancy

          -  Coagulation disorders

          -  HELLP Syndrome

          -  Eclampsia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osvaldo A Reyes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Hospital, Panama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Thomas H</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osvaldo A Reyes, MD</last_name>
      <phone>o11(507)65655041</phone>
      <email>oreyespanama@yahoo.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>January 1, 2015</last_update_submitted>
  <last_update_submitted_qc>January 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Thomas Hospital, Panama</investigator_affiliation>
    <investigator_full_name>Osvaldo A. Reyes T.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Pre-eclampsia</keyword>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Carbetocin</keyword>
  <keyword>Oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

